COV Shares Cleo Diagnostics Ltd
ASX · ASXLast in our picks 2026-10-08 — not in the current list; analysis below is from that screen
Recent positive momentum and diagnostic commercialization potential support speculative upside.
Future value: $0.48 (+54.84%) · 6-12 months
Signal breakdown
- ▸Strong recent momentum within the biotech sector.
- ▾Below 50-day MA (-7.12%)
- ▾Near 52-week low (6.3% of range)
- ▸~55% upside to price target
Is COV a buy right now?
Trend: COV is trading below the 50-day average (-7.58%), RSI 40 — neutral momentum, with a 3-month return of -8.96%.
Valuation & quality: Cleo Diagnostics Ltd trades on price-to-book 8.24; fundamentals show net margin 0.0%, return on equity -109.5%, revenue growth -100.0% year on year.
Our screen: BUY (score 2) — Recent positive momentum and diagnostic commercialization potential support speculative upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | +6.90% | -11.30% | -9.10% | -32.00% | +0.00% | -17.60% | +10.70% |
Fundamentals
Technical signals
About Cleo Diagnostics Ltd
Cleo Diagnostics Ltd, a biotechnology company, engages in the development and patent of a blood test for the detection of ovarian cancer in Australia.
Sector: Healthcare · Industry: Medical Devices · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.